{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-014156","form_type":"8-K","ticker":"BCTX","cik":"0001610820","company_name":"BriaCell Therapeutics Corp.","filed_at":"2026-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.639100+00:00","generated_at":"2026-05-15T08:10:01.093918+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"BriaPro subsidiary reports $472K net loss for six months; going concern risk","bullets":["BriaPro net loss widened to $472,231 for six months ended Jan 31, 2026 vs $233,185 a year ago.","Accumulated deficit $1.65M; negative working capital $1.64M; cash only $1.","Going concern: dependent on parent BriaCell for financing; material uncertainty noted.","On Feb 18, 2026, BriaPro agreed to acquire sCD80 license from BriaCell for cancer therapy."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-014156","json":"https://secwatch.observer/filing/0001493152-26-014156.json","markdown":"https://secwatch.observer/filing/0001493152-26-014156.md","text":"https://secwatch.observer/filing/0001493152-26-014156.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1610820/000149315226014156/0001493152-26-014156-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1610820/000149315226014156/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:10:01.093918+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}